MAPK8 and cancer: It is possible that inhibiting the activation of JNK/p38 via DUSP16 or specific inhibitors resulted in a compensatory enhancement of ERK activation due to a reduced expression of ERK-specific phosphatases in HK-1 cells, but not in other types of cancer cells.